Alembic Pharma to Hold Board Meeting on November 4 as Investors Await Second-Quarter Results
Key Facts
Alembic Pharmaceuticals listed a notice for a board meeting on November 4, 2026, in its disclosure archive. The filing is titled "Notice of Board Meeting on November 4, 2026," according to the archive published on the company’s website. The date puts the board meeting at the center of the company’s monitoring during today’s session. The available information does not include a confirmed announcement of second-quarter results or financial figures for that quarter. There is also no reliable confirmation of the stock’s movement during the November 4 session, so no price move can be linked to results that have not been verified.
The latest financial figures cited here are from the first quarter of fiscal 2027, which ended in June, when consolidated revenue rose 26% year on year to 2,150 crore rupees. Net profit increased 12% to 173 crore rupees, according to the company’s results reported by Moneycontrol. Revenue growth outpaced profit growth in the quarter, highlighting the different pace of the two financial measures during the period. These results provide a baseline for comparison with any subsequent disclosure, but they are not results for the quarter ended in September. The available information includes no confirmed figures for that quarter that would allow a new financial comparison.
Regarding the U.S. outlook for fiscal 2027, Managing Director Pranav Amin said the company had raised its business growth forecast to the mid-to-high teens, from an initial estimate of about 10–12%. The update points to an improved outlook compared with the company’s initial view, according to Moneycontrol. Amin said in May that U.S. business growth could reach 10–15% in the same fiscal year, driven by product launches and market-share gains. That earlier estimate provides a timeframe for how the outlook has evolved during the year. Neither forecast should be treated as a realized result.
Among the factors Amin cited were U.S. sales of bosutinib, saying the quarter ended in September would be the first full quarter to benefit from those sales. Exclusivity for bosutinib tablets in 100 and 500 mg strengths runs through November, according to his remarks. This sets out the period in which the drug’s sales could contribute to the company’s performance, as Amin described it. The available information, however, does not specify the sales value or their contribution to revenue or profit. The information therefore remains context for the company’s outlook, not evidence of a published second-quarter financial result.
In October, Alembic announced that it had received final approval from the U.S. Food and Drug Administration for venetoclax tablets in 10, 50 and 100 mg strengths, according to its press release. The announcement adds an approved product to the record of developments at the company in the period before the board meeting. The available information does not give details on the commercial launch date or the financial impact of the approval. The next step specified in the disclosures remains the board meeting scheduled for November 4, 2026. Any results announcement, financial update or stock reaction would require a disclosure or confirmed data not included in the available information.